

CITATION REPORT

List of articles citing

A 6-month randomized, placebo-controlled,
dose-ranging trial of topiramate for weight loss in obesity

DOI: 10.1038/oby.2003.102
Obesity, 2003, 11, 722-33.

Source: <https://exaly.com/paper-pdf/35274398/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
273	Obesity and pharmacologic therapy. 2003 , 32, 1005-24		32
272	Choosing antiepileptic drugs for developmentally normal children with specific epilepsy syndromes and behavioral disorders. 2004 , 19 Suppl 1, S39-48		1
271	Childhood obesity. 2004 , 89, 4211-8		96
270	Side effects of antiepileptics--a review. 2004 , 4, 194-203		70
269	Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. 2004 , 110, 221-31		156
268	A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. 2004 , 28, 1399-410		166
267	Current and investigational antiobesity agents and obesity therapeutic treatment targets. <i>Obesity</i> , 2004 , 12, 1197-211		164
266	Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. <i>Obesity</i> , 2004 , 12, 1658-69		105
265	Topiramate: a new potential pharmacological treatment for obesity. <i>Obesity</i> , 2004 , 12 Suppl, 167S-73S		53
264	New medication treatment options for bipolar disorders. 2004 , 110, 18-33		20
263	Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). 2004 , 61, 1-48		170
262	Modern, new pharmacotherapy for obesity. A gastrointestinal approach. 2004 , 18, 1049-72		11
261	Psychotropic drugs in the treatment of obesity: what promise?. 2004 , 18, 629-51		32
260	Circuitries involved in the control of energy homeostasis and the hypothalamic-pituitary-adrenal axis activity. 2004 , 3, 269-77		18
259	Tratamiento médico de la obesidad mórbida: alternativas actuales, límites y perspectivas. 2004 , 75, 219-224		5
258	Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. 2005 , 28, 169-75		73
257	Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine. 2005 , 46, 648-53		15

256	Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. 2005 , 59, 961-8	108
255	Safety and tolerability of emerging pharmacological treatments for bipolar disorder. 2005 , 7, 307-25	36
254	Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. 2005 , 59, 613-5	24
253	Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. 2005 , 112, 144-50	38
252	Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations?. 2005 , 86, 107-27	127
251	Medications as adjunct therapy for weight loss: approved and off-label agents in use. 2005 , 105, 948-59	26
250	Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. 2005 , 96, 243-51	57
249	Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case series. 2005 , 5, 19	17
248	Topiramate for weight reduction in Duchenne muscular dystrophy. 2005 , 31, 788-9	9
247	Differential effects of topiramate in patients with traumatic brain injury and obesity--a case series. 2005 , 179, 838-45	11
246	Review of the use of Topiramate for treatment of psychiatric disorders. 2005 , 4, 5	93
245	Drug Insight: appetite suppressants. 2005 , 2, 89-95	18
244	Overview of Pharmacologic Treatment of Obesity: Past Experiences, Present Options, and Future Directions. 2005 , 21, 319-324	1
243	Pharmacotherapy of Obesity. 2005 , 1, 15-19	1
242	Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. 2005 , 19, 873-96	94
241	Topiramate monotherapy in epilepsy and migraine prevention. 2005 , 27, 154-65	39
240	Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. 2005 , 29, 115-21	18
239	Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting. 2005 , 14, 371-80	31

238	[Weight loss with topiramate in patients with epileptic disorders]. 2005 , 124, 636-7	0
237	Pharmacotherapy for obesity. <i>Drugs</i> , 2005 , 65, 1391-418	12.1 112
236	Regulaci3n de la ingesta alimentaria: una perspectiva cl3nica. 2005 , 52, 404-430	0
235	Diabetes: are weight loss medications effective?. 2005 , 4, 65-74	18
234	The treatment of type 2 diabetes mellitus in youth : which therapies?. 2006 , 5, 201-10	9
233	Hyperthyroidism associated with topiramate treatment. 2006 , 47, 529-30	
232	Safety of drug therapies used for weight loss and treatment of obesity. 2006 , 29, 277-302	94
231	Treatments for late-life bipolar disorder. 2006 , 4, 347-64	84
230	Obesity: new perspectives and pharmacotherapies. 2006 , 14, 238-58	30
229	Reversible tremor, myoclonus, and fasciculations associated with topiramate use for migraine. 2006 , 29, 157-9	10
228	Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. 2006 , 8, 15-27	130
227	Comorbidity of eating disorders with bipolar disorder and treatment implications. 2006 , 8, 686-95	65
226	Treatment-resistant bipolar disorder. 2006 , 11, 227-40	119
225	Topiramate stimulates glucose transport through AMP-activated protein kinase-mediated pathway in L6 skeletal muscle cells. 2006 , 6, 327-32	12
224	Hypothalamic regulatory pathways and potential obesity treatment targets. 2006 , 29, 33-48	8
223	Topiramate in the treatment of compulsive sexual behavior: case report. 2006 , 6, 22	27
222	Lithium augmentation of topiramate for bipolar disorder with comorbid binge eating disorder and obesity. 2006 , 21, 425-31	11
221	Investigational therapies in the treatment of obesity. 2006 , 15, 897-915	22

220	Topiramate for the treatment of epilepsy and other nervous system disorders. 2006 , 6, 19-31	17
219	An update on the pharmacological treatment of obesity. 2006 , 22, 1463-74	14
218	The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials. 2006 , 11, 788-99	25
217	Neuropharmacology of obstructive sleep apnea and central apnea. 2006 , 21-41	
216	Topiramate for binge-eating disorder associated with obesity. 2006 , 40, 1993-7	29
215	Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. 2006 , 114, 974-84	77
214	Topiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective. 2006 , 21, 15-7	17
213	Management approaches for pediatric obesity. 2007 , 3, 810-8	26
212	Increased propensity for calcium phosphate kidney stones with topiramate use. 2007 , 6, 547-57	45
211	Preclinical Developments in Antiobesity Drugs. 2007 , 323-336	3
210	Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin. 2007 , 6, 133-45	17
209	Bupropion for weight reduction. 2007 , 7, 17-24	43
208	Pharmacological treatment of the overweight patient. 2007 , 59, 151-84	131
207	Pharmacologic treatment options for obesity: current and potential medications. 2007 , 22, 50-4	10
206	A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. 2007 , 30, 1480-6	60
205	Medical therapy for obesity--current status and future hopes. 2007 , 91, 1225-53, xi	13
204	Adjunctive topiramate treatment in refractory obese bipolar patients: a descriptive open label study. 2007 , 12, 48-53	8
203	What psychotherapists should know about pharmacotherapies for bipolar disorder. 2007 , 63, 475-90	1

202	Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. 2007 , 31, 1140-7	39
201	Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. 2007 , 9, 360-8	69
200	Use of low-dose topiramate in substance use disorder and bodyweight control. 2007 , 61, 630-3	8
199	Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. 2007 , 116, 322-7	228
198	Very-low-calorie diets: Downsizing the hospitalised obese patient. 2007 , 64, 116-120	1
197	Long-term topiramate treatment of psychotropic drug-induced weight gain: a retrospective chart review. 2007 , 29, 446-9	8
196	The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. 2007 , 63, 123-34	40
195	Pathophysiology of obesity: why surgery remains the most effective treatment. 2007 , 17, 1389-98	25
194	Malnutrition et épilepsie : des liens complexes. 2008 , 22, 88-95	1
193	Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. 2008 , 22, 822-9	16
192	Serum uric acid and lipid levels while taking topiramate for migraine. 2008 , 48, 1056-60	8
191	Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. 2008 , 14, 120-42	94
190	Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. 2008 , 30, 471-5	41
189	Medications for weight reduction. 2008 , 37, 923-42	19
188	New indications for topiramate: alcohol dependency and binge-eating disorder. 2008 , 9, 869-73	4
187	An overview of obesity in children with psychiatric disorders taking atypical antipsychotics. 2008 , 16, 69-79	17
186	Antiepileptic Drugs in Obesity, Psychotropic-Associated Weight Gain, and Eating Disorders. <i>Medical Psychiatry</i> , 2008 , 283-310	1
185	Malnutrition and epilepsy: a two-way relationship. 2009 , 28, 219-25	29

184	Gewichtsveränderungen unter Antiepileptikagabe. 2009 , 22, 163-169	
183	Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans. 2009 , 12, 87-95	37
182	The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. 2009 , 119, 233-8	38
181	Obesity and its relationship to addictions: is overeating a form of addictive behavior?. 2009 , 18, 439-51	79
180	Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. 2009 , 23, 157-62	76
179	Obesity management interventions: a review of the evidence. 2009 , 12, 305-16	14
178	2009 Edward E Smismann Award. Pharmaceutical "gold" from neurostabilizing agents: topiramate and successor molecules. 2009 , 52, 3431-40	25
177	Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate. 2009 , 2, 106-11	4
176	Topiramate weight loss in migraine patients. 2009 , 278, 64-5	17
175	Medications for obesity: mechanisms and applications. 2009 , 30, 525-38, ix	21
174	Benefits of topiramate treatment in a dual-diagnosis patient. 2009 , 50, 426-7	4
173	Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies. 2009 , 52, 7528-36	29
172	Combination therapy for obesity and metabolic disease. 2009 , 16, 353-8	24
171	Appetite suppressants, cardiac valve disease and combination pharmacotherapy. 2009 , 16, 354-64	45
170	Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. <i>Current Pharmaceutical Design</i> , 2010 , 16, 2103-12	3-3 133
169	Treatment of obesity with "combination" pharmacotherapy. 2010 , 17, 596-603	22
168	Combination drugs for treating obesity. 2010 , 10, 108-15	23
167	New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?. 2010 , 97, 63-83	56

166	Topiramate in the treatment of substance-related disorders: a critical review of the literature. 2010 , 71, 634-48		84
165	Approaches to the pharmacological treatment of obesity. 2010 , 3, 73-88		10
164	Pharmacological management of appetite expression in obesity. 2010 , 6, 255-69		98
163	Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. 2010 , 118, 218-23		82
162	Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic epilepsy receiving topiramate treatment. 2010 , 17, 1256-9		8
161	Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. 2010 , 8, 1777-801		42
160	Utilidad de los fármacos antiobesidad en la diabetes mellitus tipo 2. 2010 , 26, 161-166		
159	Pharmacotherapy for obese adolescents. <i>Pediatric Clinics of North America</i> , 2011 , 58, 139-53, xi	3.6	11
158	Drug treatment of obesity. 2011 , 34, 871-80		8
157	Medications for weight reduction. 2011 , 95, 989-1008		6
156	New drug targets for the treatment of obesity. 2011 , 90, 40-51		94
155	Eyes on the prize: The longitudinal benefits of goal focus on progress toward a weight loss goal. 2011 , 47, 853-855		2
154	Topiramate dose effects on cognition: a randomized double-blind study. 2011 , 76, 131-7		86
153	Neuropsychiatric adverse effects of centrally acting antiobesity drugs. 2011 , 17, 490-505		79
152	Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. 2011 , 377, 1341-52		611
151	Present and future: pharmacologic treatment of obesity. 2011 , 2011, 636181		36
150	Pharmacotherapy for obesity: a field in crisis?. 2011 , 6, 563-577		4
149	Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. <i>Obesity Reviews</i> , 2011 , 12, e338-47	10.6	180

148	The utility of animal models to evaluate novel anti-obesity agents. 2011 , 164, 1248-62	69
147	Emerging pharmacotherapy for obesity. 2011 , 16, 587-96	20
146	Topiramate-induced weight loss: a review. 2011 , 95, 189-99	76
145	Successful use of add - on topiramate for antipsychotic - induced weight gain. 2012 , 34, 85-6	0
144	Topiramate. 2012 , 47, 41-46	0
143	Pharmacotherapeutic Options for the Treatment of Patients with Obesity. 2012 , 28, 211-218	
142	Two anti-obesity hopefuls and their safety. 2012 , 11, 681-3	1
141	Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. 2012 , 95, 297-308	430
140	Medical therapy for the patient with obesity. 2012 , 125, 1695-703	83
139	Phentermine plus topiramate for the treatment of obesity. 2012 , 7, 503-510	1
138	Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. 2012 , 433-66	42
137	Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. 2012 , 2012, 436-438	
136	A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. 2012 , 35, 1529-39	82
135	Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. 2012 , 2012, 120-122	1
134	Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). 2012 , 20, 330-42	393
133	Central control of thermogenesis. 2012 , 63, 111-23	73
132	What is the prognosis for new centrally-acting anti-obesity drugs?. 2012 , 63, 132-46	49
131	Animal models to explore the effects of CNS drugs on food intake and energy expenditure. 2012 , 63, 124-31	10

130	Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. <i>Epilepsy and Behavior</i> , 2012 , 23, 497-9	3-2	7
129	Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. 2012 , 11, 675-91		148
128	Obesity Therapy. 2012 , 313-337		
127	Evaluation of appetite-stimulating hormones in prepubertal children with epilepsy during topiramate treatment. 2012 , 47, 423-6		7
126	Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. 2012 , 35, 4-16		113
125	Short-term topiramate treatment does not improve insulin sensitivity or secretion in obese insulin-resistant women. 2012 , 167, 839-45		4
124	[The pharmacological treatment of obesity: past, present and future]. 2012 , 153, 363-73		5
123	Pharmacological management of binge eating disorder: current and emerging treatment options. 2012 , 8, 219-41		49
122	Treatment of obesity in children and adolescents. 2012 , 17, 45-57		34
121	Pharmacological Treatment of Obesity. 2012 , 203-225		2
120	Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥ 7 kg/m ² . 2013 , 111, 1131-8		23
119	Topiramate: Effects on cognition in patients with epilepsy, migraine headache and obesity. 2013 , 6, 211-27		47
118	Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. 2013 , 21, 2163-71		133
117	Antiobesity pharmacotherapy: new drugs and emerging targets. 2014 , 95, 53-66		123
116	Treating the obese diabetic. 2013 , 6, 171-83		6
115	Effects of topiramate use on body composition and resting metabolic rate in migraine patients. 2013 , 34, 225-9		13
114	Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients?. 2013 , 15, 470-4		5
113	Management of Obesity in Older People. 2013 , 43, 145-149		

112	A review of late-stage CNS drug candidates for the treatment of obesity. 2013 , 37, 107-17	13
111	Obesity: Overview of Treatments and Interventions. 2013 , 445-464	1
110	Clinical utility of phentermine/topiramate (Qsymia) combination for the treatment of obesity. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013 , 6, 131-9	3-4 19
109	Phentermine and topiramate for the management of obesity: a review. 2013 , 7, 267-78	14
108	Combination phentermine and topiramate for weight maintenance: the first Australian experience. 2014 , 201, 224-6	10
107	Looking for Hydrogen Atoms: Neutron Crystallography Provides Novel Insights Into Protein Structure and Function. 2014 , 67, 1751	11
106	Update on obesity pharmacotherapy. 2014 , 1311, 1-13	59
105	New molecular targets in the pathophysiology of obesity and available treatment options under investigation. 2014 , 4, 209-19	3
104	Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. 2014 , 32, 1178-88	47
103	Association between topiramate and zonisamide use during pregnancy and low birth weight. 2014 , 123, 21-28	44
102	Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implications. 2014 , 19, 910-25	65
101	Topiramate use in pregnancy and the birth prevalence of oral clefts. 2014 , 23, 1017-25	52
100	New pharmacological treatments for the management of obesity. 2014 , 16, 394	25
99	Medical treatment of obesity: the past, the present and the future. 2014 , 28, 665-84	58
98	Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. 2014 , 22, 1042-9	90
97	The effect of topiramate on body weight and ghrelin, leptin, and neuropeptide-Y levels of prepubertal children with epilepsy. 2014 , 51, 220-4	19
96	The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models. 2014 , 116, 107-15	6
95	Current and emerging medications for overweight or obesity in people with comorbidities. 2015 , 17, 1021-32	48

94	Topiramate for weight reduction in adolescents with severe obesity. 2015 , 54, 19-24	30
93	Alcohol preferring (P) rats as a model for examining sex differences in alcohol use disorder and its treatment. 2015 , 132, 1-9	30
92	Past and present of antiobesity agents: focus on monoamine modulators. 2015 , 72, 697-706	15
91	Pharmacological management of obesity in pediatric patients. 2015 , 49, 220-32	31
90	Pharmacological Management of the Obese Patient. 2015 , 9, 137-156	
89	Pharmacokinetic-Pharmacodynamic Modeling to Study the Antipyretic Effect of Qingkailing Injection on Pyrexia Model Rats. 2016 , 21, 317	19
88	Stimulants for the Control of Hedonic Appetite. 2016 , 7, 105	17
87	A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus. 2016 , 26, 53-65	10
86	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. 2016 , 22 Suppl 3, 1-203	557
85	Pharmacotherapy for Obesity. 2016 , 45, 521-38	26
84	Cardiovascular Effects of the New Weight Loss Agents. 2016 , 68, 849-59	16
83	Meal replacements followed by topiramate for the treatment of adolescent severe obesity: A pilot randomized controlled trial. 2016 , 24, 2553-2561	27
82	Topiramate, zonisamide and weight loss in children and adolescents prescribed psychiatric medications: A medical record review. 2016 , 51, 56-68	14
81	Prevention and Treatment of Childhood Obesity and Metabolic Syndrome. 2016 , 829-849	
80	New Targets for Drug Treatment of Obesity. 2017 , 57, 585-605	28
79	Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?. 2017 , 54, 715-725	13
78	Epidemiology of Obesity and Pharmacologic Treatment Options. 2017 , 32, 441-462	15
77	Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. 2017 , 17, 34	28

76	Pharmacotherapy of eating disorders. 2017 , 30, 452-457		32
75	Obesity: Current and potential pharmacotherapeutics and targets. 2017 , 170, 116-147		88
74	Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. 2017 , 16, 27-39		24
73	Off-label drugs for weight management. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017 , 10, 223-234	3.4	27
72	Topiramate-induced weight loss depends on level of intellectual disability in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2018 , 83, 87-91	3.2	3
71	The Science of Obesity Management: An Endocrine Society Scientific Statement. <i>Endocrine Reviews</i> , 2018 , 39, 79-132	27.2	304
70	Bilateral acute angle closure glaucoma and myopic shift by topiramate-induced ciliochoroidal effusion: case report and literature review. <i>International Ophthalmology</i> , 2018 , 38, 2639-2648	2.2	21
69	Anorectic efficacy and safety of the diethylpropion-topiramate combination in rats. <i>Drug Development Research</i> , 2018 , 79, 225-233	5.1	3
68	New treatment modalities for obesity. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018 , 32, 535-549	6.5	22
67	Chronic Pain. 2018 , 257-263.e9		
66	Centrally Acting Agents for Obesity: Past, Present, and Future. <i>Drugs</i> , 2018 , 78, 1113-1132	12.1	52
65	Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years. <i>European Journal of Pharmacology</i> , 2018 , 836, 89-101	5.3	13
64	Treatment: New Drugs. 2019 , 464-472		
63	Precision medicine in adult and pediatric obesity: a clinical perspective. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019 , 10, 2042018819863022	4.5	12
62	Effects of different pharmacologic smoking cessation treatments on body weight changes and success rates in patients with nicotine dependence: A network meta-analysis. <i>Obesity Reviews</i> , 2019 , 20, 895-905	10.6	16
61	Topiramate Treatment of Alcohol Use Disorder in Clinical Practice. <i>Journal of Addiction Medicine</i> , 2019 , 13, 23-27	3.8	2
60	The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions. <i>Drug Discovery Today</i> , 2019 , 24, 789-795	8.8	44
59	The investigation of the effects of topiramate on the hypothalamic levels of fat mass/obesity-associated protein and neuropeptide Y in obese female rats. <i>Nutritional Neuroscience</i> , 2019 , 22, 243-252	3.6	9

58	Treatment of Metabolic Syndrome in Children. <i>Hormone Research in Paediatrics</i> , 2020 , 93, 215-225	3.3	4
57	Update on Preventive Cardiology. <i>Pediatric Clinics of North America</i> , 2020 , 67, 923-944	3.6	2
56	Topiramate-related adverse events: Pattern and signals in the Korea Adverse Event Reporting System, 2010-2017. <i>Medicine (United States)</i> , 2020 , 99, e22669	1.8	3
55	Topiramate. <i>Practical Diabetes</i> , 2020 , 37, 34	0.7	1
54	Chronic Pain. 2021 , 748-773.e5		
53	Synchronous neuronal interactions in rat hypothalamic culture: a novel model for the study of network dynamics in metabolic disorders. <i>Experimental Brain Research</i> , 2021 , 239, 755-764	2.3	1
52	Obesity: Medical and Surgical Treatment. 2021 , 131-175		
51	Metformin Treatment of Pediatric Obesity. <i>Pediatrics</i> , 2021 , 147,	7.4	3
50	Obesogenic Behavior and Binge Eating Disorder in an Elderly Female with Schizophrenia. <i>Journal of Obesity and Metabolic Syndrome</i> , 2021 , 30, 184-187	4.4	1
49	Targeting Energy Expenditure-Drugs for Obesity Treatment. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	5
48	Weight Loss during Topiramate Treatment in a Severely Obese Adolescent with Congenital Adrenal Hyperplasia and Migraine. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2021 ,	1.9	
47	Weight-Loss Drugs. 2007 , 341-368		1
46	Current Options for the Pharmacotherapy of Obesity. <i>Current Pharmaceutical Design</i> , 2019 , 25, 2019-2032	3.3	2
45	Multi-Target Drugs Against Metabolic Disorders. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2019 , 19, 402-418	2.2	6
44	Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020 , 20, 1232-1243	2.2	5
43	Psychotropic-Induced Weight Gain: Liability, Mechanisms and Treatment Approaches. <i>Medical Psychiatry</i> , 2006 , 307-354		2
42	Medical Management of Obesity Associated with Mood Disorders. <i>Medical Psychiatry</i> , 2006 , 369-416		1
41	Anti-obesity Effects of African Mango (<i>Irvingia gabonensis</i> , IGOB 131TM) Extract in Leptin-deficient Obese Mice. <i>Journal of the Korean Society of Food Science and Nutrition</i> , 2014 , 43, 1477-1483	1.5	3

40	Schizophrenia and Co-occurring General Medical Illness. <i>Psychiatric Annals</i> , 2005 , 35, 70-81	0.5	10
39	Managing overweight in older children and adolescents. <i>Pediatric Annals</i> , 2004 , 33, 39-44	1.3	8
38	Phentermine-topiramate: First combination drug for obesity. <i>International Journal of Applied & Basic Medical Research</i> , 2015 , 5, 157-8	1.1	17
37	Pharmacotherapy for obesity. <i>Journal of the Korean Medical Association</i> , 2011 , 54, 409	0.5	5
36	Current Long-Term Pharmacotherapies for the Management of Obesity. <i>Journal of Obesity and Metabolic Syndrome</i> , 2020 , 29, 99-109	4.4	3
35	Pharmacologic Treatment. 2021 , 143-169		
34	Noradrenergic, Serotonergic, Antiepileptic, and Herbal Drugs. 2004 , 267-284		1
33	Obesity and Mood Disorders. <i>Medical Psychiatry</i> , 2006 , 41-92		
32	Medical Management of Uncomplicated Obesity. <i>Medical Psychiatry</i> , 2006 , 355-368		
31	Overview of Agents with Efficacy in Binge Eating. <i>Medical Psychiatry</i> , 2006 , 289-306		
30	Pharmacologic Agents in the Treatment of Obesity. <i>Medical Psychiatry</i> , 2006 , 261-288		
29	Pharmacologic Therapy for Obesity and Overweight in Adults and Adolescents. <i>CRC Series in Modern Nutrition Science</i> , 2006 , 97-122		
28	Pharmacological Treatment of the Overweight Patient. 2007 , 203-256		1
27	Safety of Obesity Drugs. 2007 , 199-217		
26	Adult Obesity. 2007 , 869-887		
25	Epidemiology of Type 2 Diabetes in Children and Adolescents. 2007 , 357-374		
24	Obesity. 2010 , 99-114.e4		
23	Obesity and the Metabolic Syndrome. 2011 , 67-92		

22	Chronic Pain. 2011 , 935-969			1
21	References. 2011 , 283-360			
20	Medical Weight Management. 2013 , 19-37			
19	Drugs for Weight Loss and Maintenance: Present and Future. 2014 , 225-245			
18	Prevention and Treatment of Childhood Obesity and Metabolic Syndrome. 2015 , 1-25			
17	The Doctor's Tool Kit: Pharmacotherapy for the Patient with Obesity. <i>Growth Hormone</i> , 2015 , 91-109			
16	Safety of Anti-Obesity Drugs Approved for Long-Term Use. <i>The Korean Journal of Obesity</i> , 2015 , 24, 17-27			6
15	Addictive Disorders in Severe Obesity and After Bariatric Surgery. 2017 , 141-156			1
14	Obesity and schizophrenia: New drugs, new hopes. <i>Psihijatrija Danas</i> , 2020 , 52, 113-130		0.1	
13	Targeting Carbonic Anhydrase Isozymes in the Treatment of Neurological Disorders. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , 2021 , 103-120			
12	Long-Term Current Management of Enduring Obesity in Diabetes. <i>Journal of Korean Diabetes</i> , 2020 , 21, 21-26		0.1	
11	A Status of Drugs on the Horizon for Obesity and the Metabolic Syndrome—Comprehensive Review 2005. 2006 , 281-306			
10	Drugs for Weight Loss and Maintenance: Present and Future. 2014 , 225-245			0
9	Future Developments in the Area of Pharmacotherapy. 2006 , 497-512			
8	Treatment options for obesity and potential therapies on the horizon. <i>P and T</i> , 2011 , 36, 282-301		1.4	1
7	The effect of topiramate on weight loss in patients with type 2 diabetes. <i>Journal of Research in Medical Sciences</i> , 2013 , 18, 297-302		1.6	9
6	Topiramate-induced Neuropathy Mimicking Carpal Tunnel Syndrome: A Case Report. <i>Archives of Bone and Joint Surgery</i> , 2018 , 6, 78-81		1.1	1
5	Topiramate for Weight Management in Children with Severe Obesity. <i>Childhood Obesity</i> ,		2.5	0

- 4 Pharmacologic treatment of obesity. **2022**, 65, 408-416
- 3 Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. 13, 1198-1225.
- 2 AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. **2022**, 163, 1198-1225. 1
- 1 Preoperative and early adjuvant weight loss medications in bariatric surgery patients with body mass index over 60 or suboptimal initial response to surgery. **2023**, 13, 1198-1225.